Triazolo[4,5-d]pyrimidine derivatives

US9409914B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Dieter Dorsch · Ober-Ramstadt, DE
• Guenter Hoelzemann · Seeheim-Jugenheim, DE
• Kai Schiemann · Darmstadt, DE
• Ansgar Wegener · Heusenstamm, DE

Key dates

• Filing date: Dec 21, 2012
• Grant date: Aug 9, 2016
• Expiry date: Dec 21, 2032

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the formula Iin which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.